Figure 3.
(a) In vitro serum stability of Lipo-Dox and LNC-Dox over a time period of 24 h. Data are expressed as the mean ± SD (n = 3). (b) In vivo therapeutic efficacy of different doxorubicin formulations. Mice were intravenously administrated with indicated drugs (10 mg/kg) three times (day 0, day 7, and day 14) during the treatment. Data are expressed as the mean ± SD (n = 5).